939 related articles for article (PubMed ID: 30759826)
21. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
22. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
23. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
24. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
[TBL] [Abstract][Full Text] [Related]
25. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
26. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
30. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
31. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
32. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
[TBL] [Abstract][Full Text] [Related]
33. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
34. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
35. Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Saafan H; Alahdab A; Michelet R; Gohlke L; Ziemann J; Holdenrieder S; McLaughlin KM; Wass MN; Cinatl J; Michaelis M; Kloft C; Ritter CA
Cells; 2021 Mar; 10(4):. PubMed ID: 33804833
[TBL] [Abstract][Full Text] [Related]
36. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
37. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
38. Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.
Li X; Zhao X; Li C; Liu S; Yan F; Teng Y; Feng J; Miao D
Hum Cell; 2019 Jul; 32(3):360-366. PubMed ID: 31020605
[TBL] [Abstract][Full Text] [Related]
39. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
40. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
